NCT05299632

F-18 PSMA for Localization of Parathyroid Adenoma

Terminated Last updated 9 May 2025

What this trial tests

trial testing 99mTc-MIBI planar imaging and SPECT/CT. in Hyperparathyroidism in 3 participants. Terminated before completion.

Timeline

31 March 2022

Primary endpoint
9 May 2022

9 May 2022

Quick facts

Lead sponsor	Emory University
Status	Terminated
Study type	OBSERVATIONAL
Enrollment	3
Start date	31 March 2022
Primary completion	9 May 2022
Estimated completion	9 May 2022
Sites	3 locations across United States

Drugs / interventions tested

• 99mTc-MIBI planar imaging and SPECT/CT.
• F- 18PSMA PET/CT imaging study

Conditions studied

• Hyperparathyroidism — all drugs for Hyperparathyroidism →

Sponsor

Emory University

Who can join

Adults 18 to 99, any sex, with Hyperparathyroidism. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Parathyroid glands are in the neck and produce a substance called parathormone which maintains the calcium level in the blood. Sometimes one or more of the parathyroid glands become hyperactive and produce too much parathormone which causes increased calcium in the blood which can cause ill effects on multiple parts of the body.

Hyperactive glands are identified by Tc-99m Sestamibi (MIBI) scan which helps the surgeons to remove them with minimal risk to the patient. But about 30% of the time MIBI scan does not localize the hyperactive gland. There is some evidence that a new agent called F-18 PSMA (prostate-specific membrane antigen) can localize hyperactive parathyroid.

This study is being done to collect preliminary data to answer the question: Can imaging with the PET tracer, F-18 PSMA (Pylarify), prior to parathyroid surgery, provide better information to a surgeon than the standard of care imaging with MIBI scan? Patients who are scheduled for parathyroidectomy and are scheduled for imaging with MIBI scan prior to surgery will be asked to take part in this study.

This is a single institutional study to collect preliminary data to help do a larger study. Participants will get MIBI scan first, and the same day will get an F-18 PSMA scan which involves an injection in the vein, waiting an hour, and imaging of the neck and chest area for 10 minutes. The findings of F-18 PSMA will not interfere with the participant's management. Patients who participate will not directly benefit by participating in this study.

If the scanning method using F-18 PSMA shows better results than MIBI scan (standard of care) then the investigators will conduct a larger multi-institutional study. If the results prove that F-18 PSMA is better than the standard of care in the larger study, then patients with hyperactive parathyroid patients in the future will benefit.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.